Ligand Pharmaceuticals Inc. (LGND) Financials
Key financial figures for Ligand Pharmaceuticals Inc. (Q2 2026).
Ligand Pharmaceuticals Incorporated reported revenue of $63.7 million for Q2 FY2026, up 33.7% from the same period a year earlier. Net income was $48.5 million, or $2.22 per share. Operating margin came to 13.49%, against 17.73% a year earlier. Free cash flow for the period was $24.0 million. Across the last 5 reported quarters, quarterly revenue has risen from $47.6 million in Q2 FY2025 to $63.7 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Ligand Pharmaceuticals Incorporated are on the SentiSense financials page.
- Revenue
- $64M
- Net Income
- $49M
- EPS
- $2.42
- Total Assets
- $2.2B
- Operating Cash Flow
- $24M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $64M | $49M | $2.22 | 13.49% | $24M |
| Q1 FY2026 | $52M | -$13M | -$0.67 | 33.58% | $48M |
| Q4 FY2025 | $60M | $45M | $2.12 | 33.59% | $46M |
| Q3 FY2025 | $115M | $117M | $5.68 | 47.58% | $13M |
| Q2 FY2025 | $48M | $5M | $0.24 | 17.73% | $16M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $268M | $124M | $6.13 | 17.61% | $49M |
| FY2024 | $167M | -$4M | -$0.22 | -13.53% | $77M |
| FY2023 | $131M | $52M | $2.94 | 9.09% | -$4M |
Frequently asked questions
What was Ligand Pharmaceuticals Incorporated's revenue last quarter?
Ligand Pharmaceuticals Incorporated reported revenue of $63.7 million for Q2 FY2026, up 33.7% from the same period a year earlier.
Is Ligand Pharmaceuticals Incorporated profitable?
Yes. Ligand Pharmaceuticals Incorporated reported net income of $48.5 million for Q2 FY2026, a net margin of 76.16% on revenue.
How has Ligand Pharmaceuticals Incorporated's margin trended?
Operating margin was 13.49% in Q2 FY2026, compared with 17.73% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Ligand Pharmaceuticals Incorporated generate?
Ligand Pharmaceuticals Incorporated generated free cash flow of $24.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Ligand Pharmaceuticals Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.